|Bid||247.38 x 1000|
|Ask||258.87 x 1300|
|Day's range||252.51 - 259.10|
|52-week range||176.36 - 292.75|
|Beta (5Y monthly)||0.61|
|PE ratio (TTM)||31.01|
|Earnings date||27 Apr 2022 - 02 May 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||293.15|
You may be spending a little more time than you'd like these days thinking about a future market crash. But instead of letting the recent stock-market decline scare us, we should let it help us: Let's use it as a reminder that market corrections and crashes will happen.
Here's why they picked Exelixis (NASDAQ: EXEL), Moderna (NASDAQ: MRNA), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (Exelixis): If you're looking to hit a home run with an investment, it's important to look for a balance of a modest valuation and promising growth. One underrated stock that possesses all these features is cancer-fighting company Exelixis, which has a market cap of around $5.4 billion.
Alibaba, McDonald, Advanced Micro Devices, Abbott Laboratories, and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.